by Madaline Spencer | Jul 9, 2025
Fadi Fakhouri, MD, PhD, Professor of Nephrology at CHUV Lausanne, Switzerland, discusses new data on pegcetacoplan in patients with C3 glomerulopathy (C3G) and immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN). C3G is a rare...
by Madaline Spencer | Jul 8, 2025
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic (linvoseltamab-gcpt) for the treatment of adults with relapsed or refractory multiple myeloma (MM) who have received at least four prior lines of therapy, including a proteasome...
by Madaline Spencer | Jul 8, 2025
Mike Flanagan, PhD, Chief Scientific Officer at Avidity Biosciences, discusses topline results from study testing delpacibart braxlosiran (del-brax) in patients with facioscapulohumeral muscular dystrophy and the newly initiated phase 3 trial. FSHD is a rare...
by Madaline Spencer | Jul 7, 2025
The U.S. Food and Drug Administration (FDA) has approved Gammagard Liquid ERC (immune globulin infusion) for patients ages two years and older with primary immunodeficiencies. Primary immunodeficiencies are a group of rare, genetic diseases affecting the immune...
by Madaline Spencer | Jul 7, 2025
Paolo Ghia, MD, PhD, Professor of Medical Oncology at Università Vita-Salute San Raffaele in Milan, Italy, discusses results from clinical trial testing ibrutinib plus venetoclax in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL)....
